

**Gilead Sciences**

Date of publication: 30.06.2026

	Full Name  <i>(Art. 1.01)</i>	HCPs: City of Principal Practice / HCOs: City where registered  <i>(Art. 3)</i>	Country of Principal Practice  <i>(Schedule 1)</i>	Principal Practice Address  <i>(Art. 3)</i>	Unique country identifier OPTIONAL  <i>(Art. 3)</i>	Donations and Grants to HCOs / <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b &amp; 3.01.2.a)</i>			Fee for service and consultancy <i>(Art. 3.01.1.c &amp; 3.01.2.c)</i>		TOTAL OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate.</i>												
	Birgir Johannsson	Reykjavik	Iceland	Reykjafold 4				97.214	260.212	-	-	357.426	
	Hallgerður Lind Kristjánsdóttir	Reykjavik	Iceland	Reykjafold 4				160.582	364.664	-	-	525.246	
	<i>OTHER, NOT INCLUDED ABOVE- (where information cannot be disclosed on an individual basis for legal reasons)</i>												
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02												
	Number of Recipients in aggregate disclosure - Art 3.02												
<i>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02</i>								0%	0%	0%	0%	0%	
HCOs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate.</i>												
	<i>OTHER, NOT INCLUDED ABOVE- (where information cannot be disclosed on an individual basis for legal reasons)</i>												
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02												
	Number of Recipients in aggregate disclosure - Art 3.02												
	<i>% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02</i>												
R&D	<i>AGGREGATE DISCLOSURE</i>												
	Transfers of Value re Research & Development as defined in Article 3.04 and Schedule 1											-	